Literature DB >> 33579423

NAFLD-related HCC.

Bubu A Banini1, Arun J Sanyal2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the major drivers for the rising trend in hepatocellular carcinoma (HCC). Over the past three decades, the incidence of both NAFLD and HCC have increased two- to threefold. It has been forecasted that the number of patients with NAFLD in the Unites States will reach 101 million by 2030; global increase is also foreseen. This trend will likely continue to translate into increased HCC in the Unites States and across the globe. In this chapter, we summarize the current evidence linking NAFLD, metabolic syndrome, particularly obesity and type 2 diabetes mellitus, and HCC. We describe the main molecular mechanisms connecting these metabolic perturbations and hepatocarcinogenesis.
© 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Fibrosis; Hepatocellular carcinoma; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity

Year:  2021        PMID: 33579423     DOI: 10.1016/bs.acr.2020.11.001

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  3 in total

1.  Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals.

Authors:  Kitt Falk Petersen; Sylvie Dufour; Fangyong Li; Douglas L Rothman; Gerald I Shulman
Journal:  JCI Insight       Date:  2022-04-08

Review 2.  The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products.

Authors:  Gaoxuan Shao; Ying Liu; Lu Lu; Guangtao Zhang; Wenjun Zhou; Tao Wu; Lei Wang; Hanchen Xu; Guang Ji
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

Review 3.  Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?

Authors:  Ângelo Z Mattos; Jose D Debes; Arndt Vogel; Marco Arrese; Xavier Revelo; Tales Henrique S Pase; Muriel Manica; Angelo A Mattos
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.